IRLAB publishes interim report for the period January-June 2023

GOTHENBURG, SE / ACCESSWIRE / August 30, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, August 30, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company's interim report for the period January-June 2023, has been published.

SUMMARY OF THE SECOND QUARTER

• On May 3, IRLAB became aware that Ipsen's Universal Registration Document 2022, published on April 6, 2023, contained the incorrect information that the development and commercialization rights for mesdopetam had been transferred back to IRLAB. This error was corrected by Ipsen, who published an updated Universal Registration Document 2022.
• During May 2023, a discussion was initiated with Ipsen to mutually agree on the best way forward to ensure that the mesdopetam program are given the best chance of achieving registration and to ensure that mesdopetam can be made available to all people living with Parkinson's disease.
• On May 16, IRLAB and the McQuade Center for Strategic Research and Development (MSRD), part of the global pharmaceutical company Otsuka, signed an agreement that gives MSRD an exclusive right to evaluate, for a period of time, IRLAB's neuropsychiatric programs IRL757 and IRL942. The objective is to investigate whether IRLAB and MSRD, after the evaluation, can agree to enter into a collaboration to develop the compounds into medicines.
• At the end of May, it was announced that all 38 clinics are activated and recruits patients in the Phase IIb study with pirepemat. Pirepemat is developed with the goal of improving balance and reducing falls in Parkinson's disease.
• On June 13-16, IRLAB participated with a presentation at the scientific conference XIV Triennial Meeting of the International Basal Ganglia Society (IBAGS) held in Stockholm. IBAGS XIV is a major event that brings together researchers who study the basal ganglia of the brain at all levels (from molecule to behavior) in both neurological and neuropsychiatric disorders originating in the basal ganglia that also include Parkinson's disease.
• On June 20, the company's annual general meeting was held where, among other things, three new members were elected to the board; Daniel Johnsson, Christer Nordstedt and Veronica Wallin.
• IRLAB presented at several national investor conferences during the period and has ongoing discussions with potential national and international investors to continuously provide updates on the company and its development. Recordings are available on IRLAB's website, irlab.se.

EVENTS AFTER THE END OF THE PERIOD